India’s pharmaceutical industry is now the third largest in the world in terms of volume and stands 14th in terms of value. The country’s pharmaceutical market is expected to reach $55 billion in 2020 from $12.6 billion in 2009. And with a population of 1.1 billion, India is predicted to be the most populous nation in the world by 2050.
The Indian government is strongly supportive of the biopharma and biotech industries, providing infrastructure needed for the development of the industry, says Sreedhar Tirungari, M.D., senior manager, site management…
Regulatory Opportunities and Challenges
Oncology: A Differentiated Role for India
Shubhangi Desai, Ph.D. Head of Clinical Operations, Asia and North America, SIRO Clinpharm, a drug development solutions provider to the global healthcare industry. For more information, visit siroclinpharm.com.
Malavika Harita. CEO, Saatchi & Saatchi Health India, a global creative communications company and part of Publicis Healthcare Communications Group. For more information, visit saatchi.com.
Sheila Khatri. President, Moti International, which provides business development services to U.S.-based companies seeking to expand into India. For more information, visit motiintl.com.
Sanjit Singh Lamba. Managing Director and Head, Global Procurement Strategy, Eisai Knowledge Centre, India, part of Eisai Co. Ltd, a global pharma company. For more information, visit eisai.co.in and esiai.com.
Hitesh Sharma, National Life Sciences Leader and International Tax Services Leader, Ernst & Young, Mumbai, a global provider of assurance, tax, transaction, and advisory services. For more information, visit ey.com.
Sreedhar Tirungari, M.D. Senior Manager, Site Management Operations, MakroCare, a
drug development and commercialization partner for pharmaceutical, biotechnology, and medical device industries. For more information, visit makrocare.com.